Bayer Logo Bayer Logo Bayer Logo Bayer Logo

PAH FACTS

Adempas is approved for adults with PAH (WHO Group 1) and has been studied predominantly in WHO functional class II-III patients.1

SETTING AND TRACKING YOUR PAH PATIENT GOALS

The 2015 ESC/ERS Guidelines recommend follow-up assessments every 3 to 6 months for stable patients with PAH.2  Since PAH can progress rapidly, it is critical to monitor your patients often.3

ERS=European Respiratory Society; ESC=European Society of Cardiology; PAH=pulmonary arterial hypertension; WHO=World Health Organization

ASSESS AND MONITOR PATIENT RISK STATUS2*
Select a risk level:
Low Risk
Intermediate Risk
High Risk
Low Risk
Low Risk
Intermediate Risk
Intermediate Risk
High Risk
High Risk

The guidelines above can assist with:

  • Creating goals and monitoring progress to help guide the course of treatment
  • Setting goals for your PAH patients that include exercise capacity (6MWD), WHO functional class, and hemodynamics

6MWD=6-minute walk distance;

BNP=brain natriuretic peptide;

CI=cardiac index;

CMR=cardiac magnetic resonance;

NT-proBNP=N-terminal pro-brain natriuretic peptide;

pred.=predicted;

RA=right atrium;

RAP=right atrial pressure;

SvO2=mixed venous oxygen saturation;

VE/VCO2=ventilatory equivalents for carbon dioxide;

VO2=oxygen consumption

Dictionary

CLINICAL DEFINITION

PAH is defined as a mean pulmonary artery pressure (mPAP) >25 mm Hg with a pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg measured by cardiac catheterization.3

Beaker Icon

TREATMENT LANDSCAPE

The REVEAL Registry evaluated 2525 patients, of whom 2438 were on PAH treatment with ERAs, PCAs, or PDE-5 inhibitors. More than 50% of these patients remained in WHO functional class III or IV.4

Evaluation for etiologies other than PAH is appropriate in all instances.
To rule out CTEPH (WHO Group 4), a V/Q scan should be performed.3,5

CTEPH=chronic thromboembolic pulmonary hypertension; ERA=endothelin receptor antagonist; PCA=prostacyclin analog; PDE-5=phosphodiesterase type 5; V/Q=ventilation/perfusion

Alt tag

WHO GROUP CLASSIFICATION1,6

Identify which WHO group your PH patients are in.

I.PAH

II.PH due to left heart disease

III.PH due to lung disease and/or hypoxia

IV.CTEPH

V.PH with unclear multifactorial mechanisms

 

Adempas is approved for adults with PAH (WHO Group 1) and inoperable or persistent/recurrent CTEPH (WHO Group 4) after surgery. Adempas has been studied predominantly in WHO functional class II-III patients.1

PH=pulmonary hypertension

WHO GROUP CLASSIFICATION1,6

Identify which WHO group your PH patients are in.

I.    PAH

II.   PH due to left heart disease

III. PH due to lung disease and/or hypoxia

IV.  CTEPH

V.    PH with unclear multifactorial mechanisms

 

Adempas is approved for adults with PAH (WHO Group 1) and inoperable or persistent/recurrent CTEPH (WHO Group 4) after surgery. Adempas has been studied predominantly in WHO functional class II-III patients.1

PH=pulmonary hypertension

Speed Dial Icon

Learn about efficacy and safety.

Find out how Adempas can help here.

ASSESS AND MONITOR PATIENT RISK STATUS2*
Select a risk level:
Low Risk
Intermediate Risk
High Risk
Low Risk
Low Risk
Intermediate Risk
Intermediate Risk
High Risk
High Risk

The guidelines above can assist with:

  • Creating goals and monitoring progress to help guide the course of treatment
  • Setting goals for your PAH patients that include exercise capacity (6MWD), WHO functional class, and hemodynamics

6MWD=6-minute walk distance;

BNP=brain natriuretic peptide;

CI=cardiac index;

CMR=cardiac magnetic resonance;

NT-proBNP=N-terminal pro-brain natriuretic peptide;

pred.=predicted;

RA=right atrium;

RAP=right atrial pressure;

SvO2=mixed venous oxygen saturation;

VE/VCO2=ventilatory equivalents for carbon dioxide;

VO2=oxygen consumption

Dictionary

CLINICAL DEFINITION

PAH is defined as a mean pulmonary artery pressure (mPAP) >25 mm Hg with a pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg measured by cardiac catheterization.3

Beaker Icon

TREATMENT LANDSCAPE

The REVEAL Registry evaluated 2525 patients, of whom 2438 were on PAH treatment with ERAs, PCAs, or PDE-5 inhibitors. More than 50% of these patients remained in WHO functional class III or IV.4

Evaluation for etiologies other than PAH is appropriate in all instances.
To rule out CTEPH (WHO Group 4), a V/Q scan should be performed.3,5

CTEPH=chronic thromboembolic pulmonary hypertension; ERA=endothelin receptor antagonist; PCA=prostacyclin analog; PDE-5=phosphodiesterase type 5; V/Q=ventilation/perfusion

WHO GROUP CLASSIFICATION1,6

Identify which WHO group your PH patients are in.

I.    PAH

II.   PH due to left heart disease

III. PH due to lung disease and/or hypoxia

IV.  CTEPH

V.    PH with unclear multifactorial mechanisms

 

Adempas is approved for adults with PAH (WHO Group 1) and inoperable or persistent/recurrent CTEPH (WHO Group 4) after surgery. Adempas has been studied predominantly in WHO functional class II-III patients.1

PH=pulmonary hypertension

Speed Dial Icon

Learn about efficacy and safety.

Find out how Adempas can help here.

 
MORE IMPORTANT SAFETY INFORMATION LESS IMPORTANT SAFETY INFORMATION
References:
  1. Adempas Prescribing Information. Whippany, NJ. Bayer Pharmaceuticals Inc., 2021.
  2. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67-119.
  3. McLaughlin VV, Archer SL, Badesch BD, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-2294.
  4. Badesch DB, Raskob GE, Elliot CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-387.
  5. Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S85-96.
  6. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34-D41.